KALA BIO, Inc.
Close on Oct 19, 2026
- Market cap
- $14.28K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | Before market open | – | $-1.71 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | $-1.74 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | $-3.16 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 29, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 4, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 9, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 3, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 8, 2022 | Before market open | – | – | – |
Press releases
Announcements Kala Bio filed with the SEC
BIO Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
BIO Announces Strategic Initiative to Deploy and Continue to Develop an
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
BIO Settles Approximately $10.6 million of Debt
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
KALA BIO Announces Closing of $10 Million Registered
Material agreement · Other events · EX-99.2 to Form 8-K
KALA BIO Announces Topline Results from CHASE
Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
KALA BIO Announces $10,750,000 Private Placement
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
KALA BIO Announces $12,500,000 Private Placement
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Kala Pharmaceuticals Announces Reverse Stock Split
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Material agreement · Agreement terminated · Acquisition or disposition completed · Results of operations · Unregistered share sale · Executive or director change · EX-99.1 to Form 8-K